Brief: Pasithea Therapeutics Selects PAS-003 Lead Development Candidate
09/11/2023 13:08
Nov 9 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS SELECTS PAS-003 LEAD DEVELOPMENT
CANDIDATE, A HUMANIZED MONOCLONAL ANTIBODY THAT TARGETS Α5Β1
INTEGRIN FOR THE TREATMENT OF BOTH SPORADIC AND FAMILIAL ALS
* PASITHEA THERAPEUTICS CORP: FULLY HUMANIZED ANTI-Α5Β1
MONOCLONAL
ANTIBODY IS READY FOR MANUFACTURE AND IND-ENABLING STUDIES
* PASITHEA THERAPEUTICS CORP: BLOCKING OF Α5Β1 INTEGRIN HAS
BEEN
SHOWN TO IMPROVE MOTOR FUNCTION AND INCREASE SURVIVAL IN
SOD1(G93A) MOUSE MODEL OF ALS
Source text for Eikon: ID:nGNXb50xD7
Further company coverage: KTTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement